Table 2.
Vaccine effectiveness against symptomatic disease for the BNT162b2 (Pfizer-BioNTech) and mRNA-1273 (Moderna) booster vaccines in England by age group
| Age group (years) | Primary course (≥175 days after dose 2) | Booster | Interval since booster (days) | Controls | Cases | rVE (≥175 days after dose 2 baseline) (95% CI) | rVE (dose 3: 2–6 days after booster baseline) (95% CI) | VE (unvaccinated base) (95% CI) |
|---|---|---|---|---|---|---|---|---|
| 18-49 | Unvaccinated | 125,353 | 126,940 | |||||
| ChAdOx1-S | None | 61,022 | 45,988 | Baseline | 44.7 (43.7–45.6) | |||
| ChAdOx1-S | Any | 0–1 | 2,111 | 1,407 | 16.8 (10.8–22.4) | 54.5 (51.2–57.6) | ||
| ChAdOx1-S | Any | 2–6 | 3,947 | 2,467 | 22.3 (18.0–26.3) | Baseline | 57.2 (54.8–59.4) | |
| ChAdOx1-S | BNT162b2 | 7–13 | 3,984 | 736 | 76.1 (74.1–78) | 69.3 (66.2–72.0) | 86.8 (85.7–87.9) | |
| ChAdOx1-S | BNT162b2 | 14–34 | 7,174 | 561 | 89.6 (88.6–90.4) | 86.6 (85.2–87.9) | 94.3 (93.8–94.8) | |
| ChAdOx1-S | BNT162b2 | 35–69 | 2,927 | 319 | 84.4 (82.4–86.1) | 79.9 (77.2–82.3) | 91.6 (90.5–92.5) | |
| ChAdOx1-S | mRNA-1273 | 7–13 | 635 | 98 | 81.3 (76.8–84.9) | 75.9 (70.0–80.6) | 89.7 (87.2–91.7) | |
| ChAdOx1-S | mRNA-1273 | 14–34 | 342 | 13 | 95.3 (91.8–97.3) | 93.9 (89.4–96.5) | 97.4 (95.5–98.5) | |
| BNT162b2 | None | 79,181 | 29,489 | Baseline | 65.3 (64.7–65.9) | |||
| BNT162b2 | Any | 0–1 | 2,800 | 839 | 25.6 (19.4–31.3) | 73.7 (71.5–75.7) | ||
| BNT162b2 | Any | 2–6 | 6,186 | 2,046 | 21.0 (16.7–25.1) | Baseline | 71.8 (70.3–73.3) | |
| BNT162b2 | BNT162b2 | 7–13 | 8,797 | 825 | 77.9 (76.2–79.5) | 72 (69.5–74.4) | 92.1 (91.5–92.7) | |
| BNT162b2 | BNT162b2 | 14–34 | 20,595 | 1,614 | 82.8 (81.8–83.7) | 78.2 (76.5–79.7) | 93.9 (93.6–94.2) | |
| BNT162b2 | BNT162b2 | 35–69 | 16,703 | 1,707 | 77.7 (76.4–78.9) | 71.7 (69.6–73.7) | 92.1 (91.6–92.5) | |
| BNT162b2 | BNT162b2 | ≥70 | 194 | 22 | 78.1 (65.8–86) | 72.3 (56.6–82.3) | 92.0 (87.5–94.8) | |
| BNT162b2 | mRNA-1273 | 7–13 | 397 | 49 | 77.4 (69.6–83.3) | 71.4 (61.3–78.9) | 91.9 (89.0–94.0) | |
| BNT162b2 | mRNA-1273 | 14–34 | 290 | 14 | 90.9 (84.5–94.7) | 88.5 (80.3–93.3) | 96.7 (94.4–98.1) | |
| ≥50 | Unvaccinated | 10,322 | 15,481 | |||||
| ChAdOx1-S | None | 55,808 | 60,380 | Baseline | 39.4 (37.4–41.3) | |||
| ChAdOx1-S | Any | 0–1 | 4,284 | 4,212 | 12.3 (8.3–16.2) | 46.9 (44.0–49.6) | ||
| ChAdOx1-S | Any | 2–6 | 7,924 | 7,762 | 13.9 (10.9–16.8) | Baseline | 47.7 (45.3–50.0) | |
| ChAdOx1-S | BNT162b2 | 7–13 | 8,887 | 2,514 | 74.8 (73.6–75.9) | 70.7 (69.1–72.3) | 84.7 (83.8–85.5) | |
| ChAdOx1-S | BNT162b2 | 14–34 | 16,437 | 1,691 | 90.8 (90.3–91.3) | 89.4 (88.7–90.0) | 94.4 (94.1–94.7) | |
| ChAdOx1-S | BNT162b2 | 35–69 | 5,432 | 703 | 88.3 (87.3–89.2) | 86.4 (85.2–87.5) | 92.8 (92.2–93.4) | |
| ChAdOx1-S | mRNA-1273 | 7–13 | 1,275 | 317 | 78.9 (76.1–81.4) | 75.5 (72.2–78.5) | 87.2 (85.4–88.7) | |
| ChAdOx1-S | mRNA-1273 | 14–34 | 770 | 44 | 95.2 (93.4–96.4) | 94.4 (92.4–95.9) | 97 (96.0–97.8) | |
| BNT162b2 | None | 38,673 | 23,736 | Baseline | 61.2 (59.8–62.5) | |||
| BNT162b2 | Any | 0–1 | 2,753 | 1,792 | −0.7 (−7.3 to 5.5) | 61 (58.2–63.5) | ||
| BNT162b2 | Any | 2–6 | 6,474 | 3,747 | 14 (10.1–17.8) | Baseline | 66.6 (64.8–68.2) | |
| BNT162b2 | BNT162b2 | 7–13 | 9,094 | 1,812 | 71.4 (69.8–72.9) | 66.7 (64.5–68.8) | 88.9 (88.2–89.5) | |
| BNT162b2 | BNT162b2 | 14–34 | 22,158 | 2,352 | 85.6 (84.9–86.3) | 83.3 (82.2–84.2) | 94.4 (94.1–94.7) | |
| BNT162b2 | BNT162b2 | 35–69 | 15,931 | 2,119 | 81.9 (80.8–82.8) | 78.9 (77.5–80.2) | 92.9 (92.5–93.3) | |
| BNT162b2 | BNT162b2 | ≥70 | 165 | 20 | 82.1 (71.3–88.8) | 79.2 (66.6–87.0) | 93 (88.8–95.6) | |
| BNT162b2 | mRNA-1273 | 7–13 | 440 | 86 | 74.4 (67.6–79.7) | 70.2 (62.2–76.5) | 89.9 (87.3–92) | |
| BNT162b2 | mRNA-1273 | 14–34 | 374 | 39 | 86.8 (81.5–90.5) | 84.6 (78.5–89.0) | 94.8 (92.7–96.3) |
rVE, relative vaccine effectiveness compared to dose 2 (either ≥175 days after dose 2 with no booster or ≥175 days after dose 2 and 2–6 days after booster); VE, vaccine effectiveness compared to zero doses.